
|Videos|November 30, 2017
Valuable Endpoints Beyond OS in Ovarian Cancer
Author(s)Maurie Markman, MD
Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses valuable endpoints beyond overall survival (OS) that can be used in ovarian cancer clinical trials.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































